New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 21, 2014
10:02 EDTXNET, TCPI, SGGH, STAG, REGN, MTLS, LCUT, IMPR, FAF, GPRO, FNF, ECR, AMPH, ADPTOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Adeptus Health (ADPT) initiated with a Buy at Dougherty... Amphastar (AMPH) initiated with a Buy at Jefferies... Eclipse Resources (ECR) initiated with a Neutral at SunTrust... Fidelity National (FNF) initiated with a Buy at SunTrust... First American (FAF) initiated with a Buy at SunTrust... GoPro (GPRO) initiated with a Hold at Stifel... Imprivata (IMPR) initiated with an Outperform at Wells Fargo... Lifetime Brands (LCUT) initiated with a Buy at Sidoti... Materialise (MTLS) initiated with a Buy at BB&T... Regeneron (REGN) initiated with a Buy at Argus... STAG Industrial (STAG) initiated with a Buy at Sandler O'Neill... Signature Group (SGGH) initiated with a Buy at B. Riley... TCP International (TCPI) initiated with a Buy at Canaccord... Tessera (TSRA) initiated with a Buy at Craig-Hallum... Xunlei (XNET) initiated with a Perform at Oppenheimer.
News For ADPT;AMPH;ECR;FNF;GPRO;FAF;IMPR;LCUT;MTLS;REGN;STAG;SGGH;TCPI;XNET From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 24, 2014
11:07 EDTGPROGoPro retreats after Oppenheimer starts at Underperform
Shares of mountable and wearable camera developer GoPro (GPRO) are sinking after Oppenheimer initiated coverage of the stock with an Underperform rating in a note to investors. WHAT'S NEW: Although GoPro has been able to get action and adventure lovers to buy its cameras, the company will have more difficulty moving beyond that market, Oppenheimer analyst Andrew Uerkwitz wrote. To accomplish that task, the company will have to compete with smartphones and new action camera offerings, the analyst explained. Additionally, the company is valued as a social media stock, even though it has not unveiled a strategy for breaking into that space, Uerkwitz contended. He set a $45 price target on the shares. WHAT'S NOTABLE: Two other research firms earlier this month had conflicting views on GoPro, as Piper Jaffray downgraded the stock to Neutral from Overweight on valuation, but JMP Securities raised its price target on the name to $105 to $60, citing the popularity of the company's new Hero4 Black camera. Meanwhile, short selling blog Citron predicted that the stock would reach $20 in 12 months. PRICE ACTION: In late morning trading, GoPro fell 4.5% to $75.63.
10:03 EDTGPROOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:04 EDTREGNRegeneron price target raised to $460 from $350 at Canaccord
Subscribe for More Information
05:48 EDTGPROStocks with implied volatility movement; P GPRO
Stocks with implied volatility movement; Pandora (P) 69, GoPro (GPRO) 92 according to iVolatility.
October 23, 2014
18:52 EDTGPROOn The Fly: After Hours Movers
UP AFTER EARNINGS: Rubicon Project (RUBI), up 19.2%... KLA-Tencor (KLAC), up 15.8%... Gigamon (GIMO), up 13.5%... Maxwell (MXWL), up 11.3%... Qlik Technologies (QLIK), up 9.8%... NetSuite (N), up 5.5%... Microsoft (MSFT), up 3.3%... Juniper Networks (JNPR), reverses in after-hours trading and is up 1.4% after reporting third quarter results and announcing a $1.1B increase to the company's share repurchase authorization. ALSO HIGHER: Vitae Pharmaceuticals (VTAE), up 38.6% following positive top-line results from two Phase 1 clinical trials of BI1181181/VTP-37948... Pfizer (PFE), up 1.8% after announcing a new $11B share repurchase program. DOWN AFTER EARNINGS: Amazon.com (AMZN), down 10.7%... Synaptics(SYNA), down 12.7%... Pandora (P), down 6.8%... Lattice Semiconductor (LSCC), down 5.6%... Maxim Integrated (MXIM), down 5.8%. ALSO LOWER: DryShips (DRYS), down 16.5% after filing an automatic common stock shelf... NPS Pharmaceuticals (NPSP), down 7.9% following PDUFA date for Natpara extended three months to January 24... GoPro (GPRO), down 2.8% after being initiated with an Underperform at Oppenheimer.
16:07 EDTGPROGoPro initiated with an Underperform at Oppenheimer
Subscribe for More Information
07:10 EDTFAFFirst American reports Q3 EPS 74c, consensus 59c
Subscribe for More Information
October 22, 2014
10:09 EDTMTLSOn The Fly: Analyst Initiation Summary
Subscribe for More Information
October 21, 2014
16:17 EDTMTLSMaterialise initiated with a Perform at Oppenheimer
Subscribe for More Information
11:00 EDTGPROGoPro October volatility elevated on wide price movement
GoPro October weekly call option implied volatility is at 76, November is at 63, December is at 52, January is at 45; compared to its 12-week average of 58 according to Track Data, suggesting large near term price movement.
09:45 EDTIMPRImprivata, AOD Software announce partnership
Subscribe for More Information
09:36 EDTFNFFidelity National, Realogy recommended as long ideas by Robbins, Bloomberg says
Subscribe for More Information
06:02 EDTMTLSMaterialise to acquire OrthoView Holding for GBP8.47M
Materialise announced the acquisition of UK-based OrthoView Holdings. Materialise acquired OrthoView for a cash payment of GBP8.47M and a possible additional earn out payment of up to GBP360,000. At completion, OrthoView had an estimated GBP1.2M in cash and cash equivalents on hand and no financial debt. The transaction, which was signed and closed simultaneously, is expected to be accretive to earnings per share within 12 months. The transaction combines the frontrunner in 2D templating on X-ray images with Materialise's market-leading position in 3D pre-operative planning tools to provide surgeons and hospitals a one-stop shop for surgical planning software tools and corresponding 3D printed medical devices.
06:01 EDTMTLSMaterialise acquires OrthoView for GBP 8.47M
Materialise announced the acquisition of UK-based OrthoView Holdings. Materialise acquired OrthoView for a cash payment of GBP 8.47M, and a possible additional earn out payment of up to GBP 0.36M. At completion, OrthoView had an estimated GBP 1.2M in cash and cash equivalents on hand and no financial debt. The transaction, which was signed and closed simultaneously, is expected to be accretive to earnings per share within 12 months. The transaction combines the frontrunner in 2D templating on X-ray images with Materialise's market-leading position in 3D pre-operative planning tools to provide surgeons and hospitals a one-stop shop for surgical planning software tools and corresponding 3D printed medical devices.
October 20, 2014
07:16 EDTREGNAmerican Academy of Ophthalmology to hold annual meeting
AAO Annual Meeting 2014 is being held in Chicago on October 18-21.
07:10 EDTREGNAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information
07:02 EDTREGNRegeneron Sanofi begins dosing in Phase 3 study of dupilumab
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis, or AD, that is not adequately controlled with topical AD medications. LIBERTY AD CHRONOS, the first trial in the Phase 3 clinical program for dupilumab, is a randomized, double-blind, placebo-controlled, multi-national study with the primary objective of demonstrating the efficacy of dupilumab in adults with moderate to severe AD when administered concomitantly with topical corticosteroids through 16 weeks.
October 17, 2014
11:30 EDTSGGHSignature Group to acquire independent aluminum recycler for $525M
Subscribe for More Information
09:06 EDTREGNAmgen files patent infringement lawsuit against Sanofi, Regeneron
Amgen (AMGN) announced that it filed a lawsuit in the United States District Court of Delaware against Sanofi (SNY), Aventisub, formerly doing business as Aventis Pharmaceuticals, and Regeneron Pharmaceuticals (REGN) for patent infringement of U.S. Patent Numbers 8,563,698, 8,829,165, and 8,859,741. These patents, which are owned by Amgen, describe and claim monoclonal antibodies to proprotein convertase subtilisin/kexin type 9, or PCSK9. By its complaint, Amgen seeks an injunction to prevent the infringing manufacture, use and sale of Sanofi and Regeneron's alirocumab, a monoclonal antibody targeting PCSK9. Sanofi and Regeneron recently announced that they have completed Phase 3 clinical trials on alirocumab and intend to pursue regulatory approval to market alirocumab in the U.S. Amgen previously announced submission of a Biologics License Application to the FDA for evolocumab, its own investigational human monoclonal antibody to PCSK9, for the treatment of high cholesterol, on Aug. 28.
07:07 EDTREGNRegeneron announces EYLEA results from NIH study
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use